Nyxoah (NASDAQ:NYXH) Shares Down 0.4% – Time to Sell?

Nyxoah SA (NASDAQ:NYXH)’s share price fell 0.4% on Monday . The company traded as low as $4.71 and last traded at $4.73. 58,240 shares changed hands during mid-day trading, an increase of 18% from the average session volume of 49,361 shares. The stock had previously closed at $4.75.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on NYXH shares. Piper Sandler reissued an “overweight” rating and set a $9.00 price target (down from $12.00) on shares of Nyxoah in a research report on Friday, November 14th. Stifel Nicolaus lowered their target price on Nyxoah from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nyxoah in a research report on Monday, December 29th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Nyxoah has a consensus rating of “Moderate Buy” and an average target price of $11.67.

Nyxoah Price Performance

The company has a current ratio of 1.70, a quick ratio of 1.41 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $161.10 million, a price-to-earnings ratio of -1.90 and a beta of 1.55. The company’s 50 day moving average is $4.81 and its 200-day moving average is $5.51.

Nyxoah (NASDAQ:NYXH) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.13). Nyxoah had a negative return on equity of 101.99% and a negative net margin of 1,457.97%.The business had revenue of $2.31 million for the quarter, compared to analyst estimates of $1.95 million. Equities research analysts anticipate that Nyxoah SA will post -1.91 earnings per share for the current year.

Hedge Funds Weigh In On Nyxoah

Several institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE lifted its stake in shares of Nyxoah by 72.4% during the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after buying an additional 3,303 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Nyxoah in the 2nd quarter valued at about $70,000. Citadel Advisors LLC bought a new position in Nyxoah in the 3rd quarter valued at about $98,000. Shay Capital LLC bought a new position in Nyxoah in the 2nd quarter valued at about $374,000. Finally, Kovack Advisors Inc. lifted its position in Nyxoah by 148.2% during the second quarter. Kovack Advisors Inc. now owns 57,827 shares of the company’s stock worth $433,000 after acquiring an additional 34,532 shares during the last quarter.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.